reviewed april 2026|next review october 2026|88 physicians psi has verified|242 published studies
Glycine-Proline-Glutamate (GPE)
GPE (glycine-proline-glutamate) is a naturally occurring (the body's own) tripeptide cleaved from the N-terminus of IGF-1 in the brain, with neuroprotective effects independent of the IGF-1 receptor, and is the parent molecule of the FDA-approved drug trofinetide (Daybue) for Rett syndrome.
Evidence landscape: 242 published studies
Published studies span neuroprotection, GPE analog development, and trofinetide clinical trials. The native peptide's evidence is primarily from animal studies.
- 2 Human
- 188 Animal
- 10 Reviews
- 42 Other research
Enzymatically cleaved from IGF-1 by acid protease in the brain. Despite being derived from IGF-1, it does not bind the IGF-1 receptor and works through NMDA receptor modulation instead.
Trofinetide (Daybue), a synthetic cyclic analog of GPE, is FDA-approved for Rett syndrome. This validates the GPE scaffold's therapeutic relevance.
The native GPE peptide itself is not FDA-approved and has not been clinically developed. Its short half-life (minutes) limits sustained therapeutic applications.
PSI Assessment
GPE holds an unusual position in peptide research: a naturally occurring (the body's own) brain fragment that led directly to an FDA-approved drug, but is not itself clinically developed. When IGF-1 is processed in the brain, GPE is cleaved from the N-terminus and exerts neuroprotective effects through a completely different receptor system than IGF-1. Animal models show dose-dependent neuroprotection after brain injury. The synthetic analog trofinetide (Daybue) was engineered from GPE with improved pharmacokinetics and received FDA approval for Rett syndrome. The native peptide's very short half-life limits its direct therapeutic use.
The naturally occurring (the body's own) neuroprotective fragment of IGF-1. Led directly to FDA-approved trofinetide (Daybue) for Rett syndrome. Native GPE is not itself clinically developed.
GPE modulates NMDA receptor activity, reducing excitotoxicity from excessive glutamate signaling. It inhibits apoptosis through caspase-3 suppression, reduces inflammation by modulating microglial activation, and promotes astrocyte survival. The native tripeptide has a half-life measured in minutes, which is why trofinetide was specifically engineered as a cyclic analog with improved pharmacokinetics. The biological validation through trofinetide's FDA approval gives GPE stronger credibility than most early-stage (animal study) peptides, but the two molecules are related, not identical.
What the evidence supports
GPE demonstrates dose-dependent neuroprotective effects in animal models of hypoxic-ischemic brain injury, reducing infarct volume. It is enzymatically cleaved from IGF-1, confirming it as the neuroprotective moiety of that growth factor. The clinical validation of trofinetide (Daybue), a synthetic cyclic analog of GPE that is FDA-approved for Rett syndrome, confirms the therapeutic relevance of the GPE scaffold.
What is not yet established
Whether native GPE itself (as opposed to the modified trofinetide) has clinical utility. GPE has a much shorter half-life than trofinetide. Optimal delivery methods and pharmacokinetic profile for the native peptide. Applications beyond neuroprotection.
Research Evidence
The findings below cover the neuroprotective mechanism, the animal model data, and the trofinetide connection.
Evidence by condition
Evidence dimensions for GPE. Neuroprotection has consistent animal data. Clinical validation comes through the trofinetide derivative.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Neuroprotection | ||||
| Stroke/Brain Injury |
GPE is enzymatically cleaved from the N-terminus of IGF-1 by acid protease in the brain. Despite being derived from IGF-1, it does not bind the IGF-1 receptor and exerts neuroprotective effects through NMDA receptor modulation.
The receptor independence is pharmacologically important. It means GPE's neuroprotection can be studied and developed separately from IGF-1 signaling.
In animal models of hypoxic-ischemic brain injury, GPE reduces infarct volume in a dose-dependent manner. Multiple studies confirm neuroprotection against both ischemic and excitotoxic injury.
The animal neuroprotection data is consistent across research groups and injury models. This consistency supported the decision to develop a clinical analog.
Trofinetide (NNZ-2566, Daybue), a synthetic cyclic analog of GPE engineered for improved pharmacokinetics, received FDA approval for Rett syndrome based on clinical trial data.
FDA approval of a GPE analog validates the therapeutic potential of this peptide scaffold. Trofinetide was specifically engineered to overcome GPE's short half-life limitation.
2 Human|188 Animal|10 Reviews
View all 242 indexed studiesHow Glycine-Proline-Glutamate (GPE) Works
GPE (glycine-proline-glutamate) is a naturally occurring (the body's own) tripeptide cleaved from IGF-1 that provides neuroprotection through NMDA receptor modulation, independent of the IGF-1 receptor.
When IGF-1 breaks down in the brain, GPE is released and protects neurons.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
GPE is cleaved from the N-terminus of IGF-1 by acid protease. It modulates NMDA receptor activity to reduce excitotoxicity, inhibits caspase-3 to prevent apoptosis, modulates microglial activation to reduce neuroinflammation, and promotes astrocyte survival. The neuroprotective mechanism is entirely independent of IGF-1 receptor signaling. Native GPE has a half-life of minutes due to rapid enzymatic degradation. Trofinetide is a cyclic analog with improved metabolic stability.
What is Glycine-Proline-Glutamate (GPE) being studied for?
Researchers are studying Glycine-Proline-Glutamate (GPE) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Glycine-Proline-Glutamate (GPE) overall. This means a compound can have human studies for one condition but only animal data for another.
Neuroprotection
·Animal StudiesConsistent animal study data showing dose-dependent neuroprotection in hypoxic-ischemic brain injury models. The mechanism through NMDA receptor modulation is well-characterized.
Limitations: Native GPE has not been clinically developed. The very short half-life limits direct therapeutic applications. Trofinetide (the clinical analog) was specifically engineered to overcome this limitation.
Stroke/Brain Injury
·Animal StudiesAnimal models show reduced infarct size following ischemic brain injury. The neuroprotective effect is reproducible across research groups.
Limitations: No clinical translation of native GPE for stroke or brain injury. Whether the neuroprotective window is sufficient for clinical use is unknown.
Safety and Regulatory Status
FDA Status: Native GPE is not FDA-approved. The synthetic analog trofinetide (Daybue) is FDA-approved for Rett syndrome.
Availability: Research compound. Not available as a therapeutic product.
Class context: Naturally occurring (the body's own) peptide produced during normal IGF-1 processing in the brain. The FDA-approved derivative trofinetide has an established safety profile from clinical trials.
GPE is a naturally occurring (the body's own) neuropeptide. The clinical safety profile is best assessed through trofinetide (Daybue), the FDA-approved analog with established clinical trial safety data.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Glycine-Proline-Glutamate (GPE) discussion.
Comparison and Related Research
GPE is most often compared with its FDA-approved derivative trofinetide and other neuroprotective peptides.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Discovery paper identifying GPE as a neuroactive tripeptide cleaved from the N-terminus of IGF-1 in the brain, with neuroprotective properties distinct from IGF-1 receptor signaling.Sara VR et al., 1989 in Biochem Biophys Res Commun. View on PubMed
- 2.Demonstrated neuroprotective effects of the IGF-1-derived GPE peptide in adult rat models of hypoxic-ischemic brain injury, showing reduced infarct volume in a dose-dependent manner.Guan J et al., 2004 in Brain Res. View on PubMed
- 3.Evaluated the GPE analog NNZ-2566 (later developed as trofinetide) in neurobehavioral models, helping establish the translational pathway from GPE to the FDA-approved drug for Rett syndrome.Shapira S et al., 2009 in J Mol Neurosci. View on PubMed
- 4.Phase III LAVENDER trial of trofinetide (a synthetic cyclic GPE analog) demonstrating efficacy in Rett syndrome. This FDA-approved drug validates the GPE scaffold as a therapeutically relevant neuroprotective structure.Neul JL et al., 2023 in Lancet. View on PubMed
- 5.Showed that intravenous GPE infusion reduced brain injury after hypoxia-ischemia in adult rats, with the protective effect mediated through NMDA receptor modulation rather than IGF-1 receptor activation.Guan J et al., 2000 in J Cereb Blood Flow Metab. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.